Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-010601.pdf
0001179110-20-010601.rtf
0001179110-20-010601.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-010369.pdf
0001179110-20-010369.rtf
0001179110-20-010369.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-010368.pdf
0001179110-20-010368.rtf
0001179110-20-010368.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-010370.pdf
0001179110-20-010370.rtf
0001179110-20-010370.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-010351.pdf
0001179110-20-010351.rtf
0001179110-20-010351.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-010225.pdf
0001179110-20-010225.rtf
0001179110-20-010225.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-010226.pdf
0001179110-20-010226.rtf
0001179110-20-010226.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-009958.pdf
0001179110-20-009958.rtf
0001179110-20-009958.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-009959.pdf
0001179110-20-009959.rtf
0001179110-20-009959.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-009960.pdf
0001179110-20-009960.rtf
0001179110-20-009960.xls